Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Viridian Therapeutics (VRDN – Research Report). The associated price target remains the same with $46.00.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ strong financial position and promising clinical developments. The company reported a substantial cash reserve of $717.6 million, which is projected to support its operations until the second half of 2027, providing a solid financial foundation for its ongoing and future projects.
Additionally, Viridian’s recent positive topline results from the Phase III THRIVE and THRIVE-2 studies for veligrotug, a treatment for thyroid eye disease (TED), demonstrate significant clinical differentiation from current standards of care. This includes faster onset of efficacy and notable benefits for chronic TED patients. The company’s strategic plans to submit a Biologics License Application (BLA) in 2025 and a Marketing Authorization Application (MAA) in 2026 further support the potential for regulatory approval and market uptake, reinforcing the Buy recommendation.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $46.00 price target.